---
title: "BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/273249966.md"
datetime: "2026-01-21T15:00:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273249966.md)
  - [en](https://longbridge.com/en/news/273249966.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273249966.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/273249966.md) | [繁體中文](https://longbridge.com/zh-HK/news/273249966.md)


# BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances

Shares of biotech firm Aligos Therapeutics (ALGS.O) up 3% at $8.25 Co says it is testing its experimental hepatitis B drug, pevifoscorvir sodium, aimed at blocking virus replication, in a mid-stage study with 144 patients

Expects first interim data from study in early 2026, main results in 2027

ALGS says earlier tests showed the oral drug reduced infection markers

Separately, co announced that its chief medical officer, Dr Hardean Achneck, has resigned and a search for a successor is underway

ALGS was down ~25% in 2025

### 相关股票

- [Aligos Therapeutics (ALGS.US)](https://longbridge.com/zh-CN/quote/ALGS.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)

## 相关资讯与研究

- [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/zh-CN/news/278565253.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-CN/news/278556054.md)
- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/zh-CN/news/278448836.md)
- [Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market](https://longbridge.com/zh-CN/news/278917368.md)
- [Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data](https://longbridge.com/zh-CN/news/278566951.md)